DAVID J. GRAINGER - 28 Jan 2022 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role: Chief Innovation Officer
Signature: /s/ Marella Thorell, attorney-in-fact
Issuer symbol: CNTA
Transactions as of: 28 Jan 2022
Transactions value $: $248,754
Form type: 4
Filing time: 01 Feb 2022, 19:15:00 UTC
Previous filing: 02 Nov 2021
Next filing: 03 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CNTA	Ordinary Shares	Purchase	$249K	+27.5K		$9.05	27.5K	28 Jan 2022	See footnote	F1, F2
holding	CNTA	Ordinary Shares						814K	28 Jan 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2	Held by RxCelerate Limited ("RxCelerate"). The Reporting Person is a member of the board of directors of RxCelerate. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by RxCelerate, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.

Content

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Held by RxCelerate Limited ("RxCelerate"). The Reporting Person is a member of the board of directors of RxCelerate. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by RxCelerate, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.